Introduction {#Sec1}
============

Prior to the year 2000, knowledge of the genetics of paraganglioma and pheochromocytoma was confined to mutations of the *VHL*, *RET* and *NF1* genes. The identification of mutations in the succinate dehydrogenase subunit D gene (*SDHD*) in patients with head and neck paraganglioma \[[@CR1]\] was therefore a major breakthrough. The association of paraganglioma with mutations in *SDHD*, and later with mutations in other SDH subunits, has helped elucidate both the role of the mitochondrial SDH complex and intermediary metabolism in tumorigenesis. The subsequent discovery of SDH mutations in patients with pheochromocytomas and extra-adrenal paragangliomas \[[@CR2]\] led to a recognition that paragangliomas and pheochromocytomas share not only similar cellular origins, but can also have a comparable genetic basis.

Paragangliomas of the head and neck are generally benign tumors that arise in the paraganglion tissue associated with the autonomic nervous system. Paragangliomas most frequently arise in the head and neck region, as carotid body tumors in the carotid bifurcation (approximately 80%). Other frequently seen locations within the head and neck region are along the jugular bulb or tympanic nerve (17.5%), or the paraganglia along the vagal nerve (4.5%) \[[@CR3]\].

Pheochromocytomas and extra-adrenal paragangliomas are tumors associated with the sympathetic nervous system, are commonly described as sympathetic paragangliomas (sPGLs), and show a close embryological and physiological relationship to head and neck paragangliomas. They are most commonly derived from the chromaffin cells of the adrenal medulla (pheochromocytoma), but approximately 10--20% occur elsewhere in the abdomen \[[@CR4]\], but can occur from the neck to the pelvic floor in any of the sympathetic paraganglia. Extra-adrenal sympathetic paragangliomas show a greater degree of malignancy than either pheochromocytomas or head and neck paragangliomas \[[@CR5]\].

Here we discuss recent advances in the understanding of the genetic basis of both head and neck paragangliomas and pheochromocytomas, and further developments relevant to the genetic diagnosis of these tumors.

Genetics {#Sec2}
========

Presently, causative gene mutations can be identified in around 32% of paraganglioma-pheochromocytomas \[[@CR6]\]. Hereditary tumor syndromes which have pheochromocytoma within their spectrum include the multiple endocrine neoplasia syndromes, MEN2A and MEN2B, caused by mutations of the *RET* (Rearranged in Transfection) proto-oncogene, subtypes of von Hippel-Lindau (*VHL*) disease, caused by mutations of the VHL tumor suppressor gene, and neurofibromatosis type 1 (*NF1*) resulting from mutations of the *NF1* tumor suppressor gene \[[@CR7]\]. These syndromes account for around 17% of cases \[[@CR6]\] but are rarely associated with head and neck or extra-adrenal paragangliomas.

More recently, mutations in genes associated with the mitochondrial succinate dehydrogenase (SDH) complex (*SDHA*, *SDHB*, *SDHC*, *SDHD* and *SDHAF2*) have been shown to cause head and neck paragangliomas, extra-adrenal paragangliomas, and pheochromocytomas (Table [1](#Tab1){ref-type="table"}) \[[@CR1], [@CR2], [@CR8]--[@CR11]\]. These genes account for the remaining 15% of cases \[[@CR6]\]. All of these genes are tumor suppressors, showing loss of heterozygosity (LOH), the loss of the normal allele in the tumor, in conjunction with the germline mutation. This results in loss of a protein subunit, which in turn destabilizes the SDH complex and abolishes its enzymatic activity \[[@CR12]\].Table 1Summary of genes, known protein functions and related syndromesGeneLocusProtein functionGene mechanismNo. of unique mutations^a^SyndromePrimary locationsSDHD11q23One of the two transmembrane subunits of Complex II of the respiratory chainAutosomal dominant with LOH + imprinting110Hereditary paraganglioma/pheochromocytomaHead and neck; parasympathetic trunkSDHB1p36.1-p35The iron-sulfur protein catalytic subunit of Complex IIAutosomal dominant with LOH175Hereditary paraganglioma/pheochromocytomaAbdominal/thoracic paraganglia, adrenal; sympathetic trunkSDHC1q23.3One of the two transmembrane subunits of Complex II of the respiratory chainAutosomal dominant with LOH34Hereditary paraganglioma/pheochromocytomaHead and neck; parasympathetic trunkSDHAF211q12.2Mitochondrial assembly factor for Complex II---interacts directly with SDHAAutosomal dominant with LOH + imprinting1Hereditary paraganglioma/pheochromocytomaHead and neck; parasympathetic trunkSDHA5p15The flavoprotein catalytic subunit of Complex IIAutosomal dominant with LOH1Hereditary paraganglioma/pheochromocytomaAbdominal paraganglia, sympathetic trunkSDHA5p15The flavoprotein catalytic subunit of Complex IIAutosomal recessive7Mitochondrial encephalopathy/Leigh SyndromeSystemicSDHAF119q13.12Mitochondrial assembly factor for Complex II. Interacts directly with SDHB?Autosomal recessive2Infantile leukoencephalopathySystemicTMEM1272q11.2Transmembrane protein involved in protein traffickingAutosomal dominant with LOH8Hereditary pheochromocytomaAdrenal; sympathetic trunk^a^Number of mutations derived from the literature or the TCAC gene mutation database \[[@CR34]\]

Succinate dehydrogenase is an enzyme of the mitochondrial tricarboxylic acid cycle, and also plays an important role as the complex II component of the electron transport chain, contributing to the generation of ATP by oxidative phosphorylation. These combined roles place SDH at the center of two of the essential energy producing processes of the cell. SDHA is a flavoprotein, and SDHB, an iron-sulfur protein, and together they form the main catalytic domain, while SDHC and SDHD are the membrane-anchoring subunits of SDH and play a role in passing electrons through the electron transport chain. Despite the fact that SDH proteins are all components of the same protein complex, mutations lead to clear differences in clinical phenotype. The molecular basis for this clinical divergence is not currently known.

SDHD {#Sec3}
====

Researchers in the Netherlands were the first to successfully tackle the genetics of head and neck paraganglioma \[[@CR13]--[@CR18]\] and they were greatly assisted by the unusual social and demographic history of the country. Until relatively recently, the Netherlands was characterized by significant religious, social, and geographic obstacles to intermarriage, leading to the creation of many genetically isolated populations \[[@CR19]\]. Such populations facilitate the proliferation of founder mutations, one of them being the well-known Dutch *SDHD* founder mutation, p. Asp92Tyr \[[@CR20]\]. The increased prevalence of this and other *SDHD* founder mutations, relative to *SDHB* mutations, facilitated the initial mapping of the *SDHD* locus \[[@CR13], [@CR14]\].

The subsequent identification of the gene in 2000 \[[@CR1]\] represented a significant discovery as it was the first time that a mitochondrial protein was show to be a tumor suppressor. It was also the first protein with a role in intermediary metabolism to be directly linked to tumorigenesis. Mutations in *SDHD* most frequently result in benign head and neck paragangliomas and are much less commonly associated with sympathetic paragangliomas and adrenal pheochromocytomas \[[@CR21]\]. The proportion of *SDHD* mutation carriers that will develop a tumor (penetrance) is high (87--100%), although not all carriers with a tumor will develop additional tumor-related symptoms \[[@CR22], [@CR23]\].

SDHB {#Sec4}
====

The identification of mutations in *SDHD* as a cause of hereditary paraganglioma syndrome quickly led to the discovery of the role of other SDH subunits. *SDHB* plays a major role in hereditary paraganglioma syndrome \[[@CR2]\], and is now known to be a significant cause of adrenal pheochromocytomas, but is chiefly associated with extra-adrenal paragangliomas \[[@CR6]\]. Since its discovery, *SDHB* has been found to be the dominant gene in hereditary paraganglioma syndrome in many parts of the world, despite a relatively low penetrance of *SDHB* mutations of 25--40% \[[@CR24]--[@CR26]\]. Due to their lower penetrance, *SDHB* mutations are often found in apparently sporadic patients \[[@CR27]\]. *SDHB* mutations primarily predispose to sPGLs, and around 20% of *SDHB* mutation carriers will develop metastatic disease \[[@CR5], [@CR6]\].

SDHC {#Sec5}
====

*SDHC* was the second SDH subunit gene identified as a cause of paragangliomas \[[@CR11]\]. Paragangliomas due to mutations in *SDHC* are much rarer than *SDHB*- and *SDHD*-related paragangliomas, accounting for less than 1% of all patients in a recent study \[[@CR6]\]. *SDHC* mutations result primarily in head and neck paragangliomas, but have also been identified in patients with sympathetic paragangliomas \[[@CR28], [@CR29]\].

SDHAF2 {#Sec6}
======

While the role of the *SDHB*, *SDHC* and *SDHD* genes in paraganglioma/pheochromocytoma has been known for a number of years, several novel SDH-related genes have only been identified very recently. The first was a gene encoding a novel protein involved in the addition of the flavin-adenine dinucleotide (FAD) prosthetic group to form the active SDHA flavoprotein \[[@CR10]\]. While the approximate location of this paraganglioma-associated gene had been known for over a decade, referred to as PGL2 locus \[[@CR15], [@CR16]\], a yeast screen of respiration deficient mutants facilitated the fortuitous discovery of a conserved mitochondrial protein of unknown function that physically associated with the SDHA flavoprotein. Initially named SDH5, the succinate dehydrogenase complex assembly factor 2 (*SDHAF2*) was shown to be essential for the correct flavination of SDHA and function of the SDH complex. A missense mutation of *SDHAF2* c.232G\>A (p.Gly78Arg) identified in a large Dutch head and neck paraganglioma kindred results in the loss of SDHA flavination and activity of the SDH complex \[[@CR10]\].

In a follow-up study with the joint aims of identifying new mutation carriers and assessing the frequency of *SDHAF2* mutations amongst 443 paraganglioma and pheochromocytoma patients, it became clear that mutations in this gene make a very modest contribution to the overall genetic burden in these syndromes \[[@CR8]\]. No mutations of *SDHAF2* were identified in any patient with a pheochromocytoma, and all currently affected mutation carriers have head and neck paraganglioma exclusively. Only one additional *SDHAF2*-related family was identified, which interestingly carried the exact mutation, p.Gly78Arg, previously found in the Netherlands, but without evidence of a familial relationship to the Dutch kindred \[[@CR8]\]. Although apparently a simple loss of function mutation in yeast \[[@CR10]\], the recurrence of this mutation and absence of other mutations \[[@CR8], [@CR30]\] may suggest that the *SDHAF2* protein with the specific p.Gly78Arg mutation retains residual activity, allowing the protein to participate in other, currently unknown, cellular activities, most feasibly the addition of FAD prosthetic groups to other flavoproteins.

A striking aspect of *SDHAF2* mutations, and the probable explanation for the rapid identification of all mutation carriers, is the very high penetrance. Of the 42 identified mutation carriers thought to be at risk, 37 are known to have developed a tumor. All currently unaffected mutation carriers are under the age of 45. This level of penetrance will usually lead to a familial presentation and such families will have already come to the attention of clinicians. Seven mutation carriers are known to have inherited the mutation via the maternal line, and are not thought to be at risk of tumor development (see \"[Inheritance](#Sec10){ref-type="sec"}\" below).

The studies above suggest that *SDHAF2* mutation screening should only be considered in patients who suffer exclusively from head and neck paragangliomas, who have familial antecedents, multiple tumors, or a very young age of onset, and in whom the *SDHB*, *SDHC* and *SDHD* genes have been shown to be negative for mutations and deletions by sequencing and multiplex ligation-dependent probe amplification (MLPA).

SDHA {#Sec7}
====

The identification of SDHAF2 as a paraganglioma-related tumor suppressor that interacts with SDHA was unexpected, as *SDHA* itself was the only SDH subunit gene not known to be mutated in paraganglioma cases. *SDHA* is the largest gene and protein of the SDH complex and is the major catalytic subunit of the enzyme. For 10 years following the discovery of *SDHD*, it remained a mystery why no mutations of *SDHA* could be found in paraganglioma patients, a mystery which deepened with the identification of *SDHAF2* as a paraganglioma-related tumor suppressor gene. Recently the first *SDHA* mutation was reported, (c.1765C\>T, p.Arg589Trp---exon 13) in a patient with a catecholamine secreting extra-adrenal paraganglioma \[[@CR9]\]. This patient had no family history of paraganglioma or any related endocrine syndrome.

It remains unclear why *SDHA* mutations in paragangliomas are so rare, but the patient above may suggest that *SDHA* mutations show reduced penetrance and most mutation carriers escape the development of clinical symptoms. Equally, and as suggested above for *SDHAF2*, the scarcity of *SDHA* mutations could be attributable to a secondary cellular function of SDHA, leading to intolerance for missense and truncating mutations that eliminate all enzyme activity.

The most stable of the SDH proteins when soluble, SDHA has been reported to be a component of a mitochondrial ATP-sensitive potassium channel \[[@CR31]\]. While SDHB also seemed to be involved in this complex, the main protein interaction was between SDHA and the mitochondrial ATP-binding cassette protein 1 (mABC1), and the complex could be inhibited by 3-nitropropionate (NPA), a specific inhibitor of SDHA \[[@CR32]\]. Whether the maintenance of this complex is essential to cell viability remains to be determined.

Alternatively, if we assume that an LOH event which deletes the remaining normal allele is required for tumorigenesis, loss of essential genes in the proximity of *SDHA* may not be tolerated, or other local genomic factors may be preventing the secondary LOH event. An exact molecular description of the LOH event in the case described by Burnichon et al. \[[@CR9]\] and in any subsequent cases may provide useful insights.

A few rare cases of congenital SDHA deficiency due to homozygous recessive mutations are known \[[@CR33]--[@CR35]\]. While the patients themselves tend to be severely affected by developmental abnormalities or cardiomyopathy early in life, due to mitochondrial deficiency, the heterozygous parents of these patients have never been reported to develop paraganglioma, perhaps suggesting that LOH events are indeed rare in conjunction with mutations of *SDHA*.

Mutations seen in these patients are generally missense and the only known truncating mutation in a patient was found together with a missense mutation on the opposing allele \[[@CR36]\], suggesting that complete loss of SDHA function may not be compatible with life.

Whether the patient described by Burnichon et al. \[[@CR9]\] will prove to be first of many paraganglioma cases related to *SDHA* mutations is presently unclear. The current significance of *SDHA* in the clinical management of paraganglioma-pheochromocytoma is minimal, but this may change if future studies identify additional mutation carriers.

SDHAF1 {#Sec8}
======

The identification of *SDHAF2* as a paraganglioma gene underlines the curious fact that another recently identified gene is not currently known to be involved in paraganglioma, but may nevertheless further our understanding of the role of SDH in paraganglioma formation. Succinate dehydrogenase complex assembly factor 1 (SDHAF1) \[[@CR37]\] is a novel LYR-motif protein; the first SDH assembly factor identified in any organism, and is located within the mitochondrial matrix. Identified in consanguineous families of Turkish and Italian origin, homozygous mutations of the *SDHAF1* gene result in infantile leukoencephalopathy in affected children, and symptoms include rapidly progressive psychomotor regression beginning in the first year of life, reminiscent of the clinical symptoms seen in homozygous *SDHA* mutations carriers \[[@CR38]\]. Patients show defective succinate dehydrogenase (complex II), with only 20--30% residual activity in muscle and fibroblasts, and the accumulation of lactate and succinate in the brain white matter. Disruption of the homologous gene or expression of the mutated gene in yeast caused SDH deficiency and failure of oxidative phosphorylation-dependent growth. Because the LYR tripeptide motif found in SDHAF1 is also seen in several iron-related proteins and may be a signature for proteins involved in Fe--S metabolism, this protein may well be associated with the SDHB subunit.

Loss of SDHB is currently thought to be central to tumorigenesis in paragangliomas \[[@CR39]\], but none of the parents in *SDHAF1* families, who are heterozygous mutation carriers, have been reported to develop paragangliomas. The explanation for the lack of tumor development in these mutation carriers and heterozygous *SDHA* mutation carriers may lie in the biochemical activity of SDH-complex II. *SDHA* homozygous mutation carriers generally show retention of complex II activity of at least 20% (range 20--61%) \[[@CR33], [@CR35]\], and likewise, homozygous *SDHAF1* mutation carriers show 20--30% residual activity. In contrast, SDH-related tumors, including *SDHD* \[[@CR12]\], *SDHB* \[[@CR40]\], *SDHA* \[[@CR9]\] and *SDHAF2* \[[@CR12]\] carry an inactivating mutation which, combined with the loss of the wild type allele (LOH), results in almost complete loss of activity. As *SDHAF*1 and most *SDHA* mutations do not eliminate all enzyme function, even allowing for LOH in a specific cell, a residual activity of 10--30% is apparently sufficient to prevent the development of paragangliomas.

A further interesting aspect of the biochemical profile of *SDHAF1* and *SDHA* mutation carriers is the accumulation of succinate. In both cases succinate will accumulate \[[@CR37], [@CR41]\] and can lead to the nuclear translocation of hypoxia-inducible factor 1 (HIF-1) \[[@CR41]\]. The nuclear translocation of HIF-1 may be an important mechanism in triggering tumorigenesis in paraganglioma progenitor cells \[[@CR42], [@CR43]\], but its occurrence in *SDHAF1* and *SDHA* mutation carriers may suggest that complete loss of SDH activity is required to achieve levels of succinate accumulation sufficient to drive HIF-1 translocation to the extent needed to initiate tumorigenesis. For a detailed discussion of these and other recent developments in the understanding of the molecular basis of tumorigenesis, we refer readers to a recent review \[[@CR43]\].

Although none of the heterozygous mutation carriers in *SDHAF1* families currently seem susceptible to the development of paragangliomas-pheochromocytomas, the recent example of *SDHA* \[[@CR9]\] emphasizes that no SDH-related gene can be entirely excluded when one is considering the genetics of these tumors.

TMEM127 {#Sec9}
=======

In addition to the recently reported genes related to succinate dehydrogenase, a novel tumor suppressor gene associated with a clinical phenotype of exclusively adrenal pheochromocytoma has also been described \[[@CR44]\]. The gene encodes a putative transmembrane protein, TMEM127, and is found on chromosome 2q11. TMEM127 is a highly conserved and broadly expressed protein with three transmembrane regions, but has no known functional domains. Transfection experiments showed that the protein is found in both the plasma membrane and the cytoplasm, and suggested that TMEM127 may participate in protein trafficking between the plasma membrane, golgi and lysosomes.

Previous gene expression studies have indicated that pheochromocytomas fall into two broad categories based on the transcriptional profile \[[@CR45]\], which may translate to the molecular pathways leading to tumorigenesis. SDH and VHL associated tumors show a signature of angiogenesis, hypoxia, enhanced expression of the extracellular matrix, and reduced expression of components of the oxidative response and tricarboxylic cycle. Tumors linked to *NF1* or *RET* mutations show an upregulation of biological pathways including genes that mediate translation initiation, protein synthesis, and kinase signaling, and are both associated with the RAS/RAF/MAP kinase signaling pathway \[[@CR45]\].

*TMEM127*-related pheochromocytomas show a transcriptional profile similar to *NF1* and *RET* related tumors \[[@CR44]\]. However, neither RAS activation nor AKT phosphorylation was seen, indicating that TMEM127 loss is not identical to either NF1 or RET. The authors focused on the mammalian target of rapamycin (mTOR), which is deregulated on loss of NF1, and could show that the C1 mTOR complex is specifically affected by TMEM127 knockdown, leading to increased phosphorylation of targets of mTORC1. Knockdown of TMEM127 also resulted in larger cells with higher rates of proliferation. Pheochromocytomas carrying a *TMEM127* mutation showed hyperphosphorylation of mTOR effector proteins, all these data together indicating that TMEM127 is a negative regulator of mTOR.

The authors were able to identify mutations in 4 out of 12 families without known mutations in other susceptibility genes, and in 3 of 83 apparently sporadic patients. Of the seven distinct germline mutations identified, six were truncating, and the deletion of the wild-type allele in tumor DNA indicates that this is a bone fide tumor suppressor gene.

The identification of *TMEM127* underlines that there are several pathways that can lead to adrenal, extra-adrenal, and head and neck paragangliomas. Whether there are important links between the essential molecular pathways of NF1, RET, and TMEM127 on the one hand and the VHL and SDH-related proteins on the other, is presently unclear, but hypoxia can regulate both HIF-1 and mTORC1 \[[@CR46]\], perhaps related to expression of BCL2/Adenovirus E1B 19-KD protein-interacting protein 3 (BNIP3) \[[@CR47]\]. As each of these genes is associated with patterns of biological and clinical expression that are not yet understood, it is clear that we are only at the beginnings of our knowledge of these syndromes.

Inheritance {#Sec10}
===========

Inheritance of paraganglioma syndrome differs significantly dependent on the gene involved. While *SDHB*- and *SDHC*-linked paraganglioma families show normal autosomal dominant inheritance, *SDHD* and *SDHAF2* linked families show an exclusively paternal transmission of tumor susceptibility \[[@CR10], [@CR18]\]. The recognition of this phenomenon was made possible by the same social and demographic factors in the Netherlands that facilitated the initial mapping of the *SDHD* locus, and specifically by the increased prevalence of *SDHD* mutations, relative to *SDHB* mutations. Although mutations in *SDHD* and *SDHAF2* can be inherited via the maternal and paternal lines, tumor formation following maternal transmission of a mutation is extremely rare \[[@CR18], [@CR48]\].

The failure of maternally transmitted mutations to initiate tumorigenesis initially suggested that an imprinted gene expressed only from the paternal allele could be the underlying cause of the tumor \[[@CR18]\]. The subsequent identification of SDHD, with its central role in cell biology, called this assumption into question. It was also established that the gene does not show mono-allelic expression, at least in the tissues analyzed to date \[[@CR1], [@CR49]\]. The concept of gene expression of *SDHD* exclusively from the paternal allele is also contradicted by the normal development of mutation carriers with a paternally inherited mutation.

The additional occurrence of this phenomenon in paraganglioma families linked to *SDHAF2*, (like *SDHD*, located on chromosome 11), while it is absent in *SDHB*- and *SDHC*-related tumors (both genes located on chromosome 1), suggested that chromosomal location could be a factor in *SDHD* and *SDHAF2* related tumors.

It is known that the entire maternal copy of chromosome 11 is lost in many paragangliomas \[[@CR49]--[@CR51]\]. Although *SDHD* and *SDHAF2* themselves seem not to be imprinted, the main cluster of imprinted genes in the human genome is located on the same chromosome, at 11p15.5. This suggests a model \[[@CR48], [@CR49]\] in which a maternally expressed, paternally imprinted gene is an essential initiator or modifier of tumor development in these syndromes. Indeed, the only report to date that has claimed to show the maternal transmission of tumor susceptibly together with an *SDHD* mutation showed that the patient had also acquired an altered methylation profile and therefore probably an altered imprinted status of *H19*, a known paternally imprinted tumor suppressor gene on 11p15 \[[@CR48], [@CR52]\].In addition, it is known that *VHL*-related pheochromocytomas \[[@CR53], [@CR54]\] also show loss of the maternal copy of the chromosome 11p15.5 region specifically, indicating that this model may have wider importance.

High altitude paraganglioma {#Sec11}
===========================

Long before the identification of any of the genes now known to play a role in paraganglioma, it was recognized that living at high altitude can have a profound influence on the development of carotid body hyperplasia and carotid body tumors \[[@CR55]--[@CR57]\]. A number of mammalian species are known to develop pronounced hyperplasia or tumors with a prevalence of up to 10% in humans and up to 40% in bovines \[[@CR58], [@CR59]\], in contrast to an estimated low altitude prevalence of head and neck paraganglioma of 1 in 500,000 or less.

This increased prevalence and the central role of the carotid body in oxygen sensing suggested a role for oxygen sensing in the tumorigenesis of paragangliomas. The identification of succinate dehydrogenase and subsequent molecular studies has affirmed this link. A number of studies have linked the central mediator of cellular hypoxia, HIF-1, to defects in succinate dehydrogenase \[[@CR60]\]. These studies postulate that a so-called 'pseudo-hypoxia' results from the inhibition of succinate dehydrogenase, leading to the accumulation of succinate, resulting in the activation of HIF-1 through the inhibition of prolyl hydroxylase-mediated degradation \[[@CR42], [@CR61]\]. The HIF-1 transcription factor complex \[[@CR62]\] initiates the transcription of a range of genes that mediate an adaptive response to reduced oxygen. How the activation of the HIF-1 protein may lead to the initiation of tumorigenesis in the carotid body and the exact relation of physiological hypoxia to molecular 'pseudo-hypoxia' awaits further investigation. Despite this suggestive link, the possible role of succinate dehydrogenase mutations in high altitude paraganglioma cases has received little attention and the first genetic analysis failed to identify any mutations \[[@CR63]\]. Recently, Cerecer-Gil et al. \[[@CR64]\] identified a family with two *SDHB*-linked cases of high altitude paraganglioma, residing at elevations of up to 2,200 m. These are the first cases to link high altitude paraganglioma to mutations of the succinate dehydrogenase genes. While the occurrence of paraganglioma in this family could be purely coincidental to their place of residence, two factors indicated that elevation may be playing a role in the expression off these tumors. One of the patients showed a remarkably aggressive recurrent tumor, which achieved a volume almost equivalent to the original tumor within 2 months of excision. This behavior is in sharp contrast with the indolent growth pattern normally seen in head and neck paragangliomas, with a mean doubling rate of 4.2 years \[[@CR65]\]. In addition, both patients developed head and neck tumors, while abdominal tumors occur much more frequently in *SDHB* mutation carriers. The identification of *SDHB* mutations in high altitude paraganglioma may serve to renew interest in this fascinating but underappreciated field of paraganglioma research, and refocus attention on the role of oxygen levels in the initiation and development of these tumors.

New strategies in mutation analysis {#Sec12}
===================================

The importance of the SDH-related genes in paraganglioma-pheochromocytoma has led to extensive genetic screening of patients, even in the absence of clear familial antecedents. In patients with pheochromocytomas, in addition to the SDH genes, the *RET* and *VHL* genes should also be screened. The costs involved in analyzing all of these genes can be considerable, and are increasing with each new gene identified. Efforts have been made to use clinical data to derive algorithms to guide rational genetic testing, with the aims of efficiency and cost reduction \[[@CR6], [@CR21], [@CR66]\]. Perhaps the most comprehensive of these is that proposed by Mannelli et al. \[[@CR6]\], but even this is now in need of updating. Such algorithms are now widely used and assist the rapid identification of mutation carriers, but many patients may provide few useful clinical parameters, or may not conform to the rather broad criteria of these algorithms.

Mutation analysis is generally carried out using DNA sequencing, but this technique can rarely detect large deletions. Both MLPA \[[@CR67]\] and similar multiplex PCR methods \[[@CR68]\] have been applied in SDH deletion analysis, and have led to the recognition that deletions can represent up to 10% of all mutations \[[@CR69]\].

While algorithms have improved the efficiency of genetic testing, recently a supplementary approach has been developed with the use of SDHB immunohistochemistry. As originally noted by Douwes Dekker et al. \[[@CR12]\], paragangliomas show loss of staining for the iron protein component of SDH, encoded by *SDHB*. This finding was subsequently explored by van Nederveen et al. \[[@CR39]\] who showed that in a series of 220 paragangliomas and pheochromocytomas, 102 tumors with known mutation of one of the SDH genes were negative for SDHB staining while *RET*, *VHL* and *NF1* cases were uniformly positive. Only six cases were found to be negative and not explained by a known mutation in one of the SDH genes. This translates to a sensitivity of 95% (C.I. 87--100%) and specificity of 84% (C.I. 60--97%).

The utility of this approach was subsequently confirmed in an independent series of tumors by Gill et al. \[[@CR70]\] and was also shown to be useful in identifying the gastrointestinal stromal tumor (GIST) component of the Carney triad (CT) \[[@CR71]\]. Showing that a GIST is a legitimate constituent of this tumor syndrome would potentially allow earlier diagnosis, when compared to current methods which focus on clinical criteria and require the co-occurrence of paraganglioma and pulmonary chondroma. These authors also showed that some cases of apparently sporadic GISTs also show loss of SDHB staining and propose that these represent a new subtype of GISTs.

The development of a reliable SDHB immunohistochemical procedure and the demonstration that SDHB staining can accurately distinguish SDH-related cases from other groups represents an important advance, where tumor material is available. As head and neck paragangliomas are often not operated for a considerable period after initial diagnosis, while most pheochromocytomas will be removed upon diagnosis, phaeochromocytomas represent the most useful group of tumors for the application of this technique.

Conclusion {#Sec13}
==========

The last 10 years have seen enormous progress in the field of head and neck paraganglioma and pheochromocytoma genetics. Six new genes have been added to a list that previously included only *VHL*, *RET* and *NF1*, and the number of patients in whom a gene mutation can be identified has doubled, and now stands at around 30--35%. New techniques related to mutation analysis, including analysis algorithms, MLPA and SDHB immunohistochemistry, have improved the efficiency and accuracy of genetic analysis.

The identification of mutations in *SDHAF2* has revealed that proteins ancillary to succinate dehydrogenase can also be tumorigenic, and the belated identification of a mutation in *SDHA* in a paraganglioma patient has demonstrated that no SDH-related gene can be entirely excluded from consideration when thinking about the genetics of these tumor syndromes.

Finally, the recent identification of *TMEM127* by Dahia et al. \[[@CR44]\] has shown that entirely novel genes may be related to these tumor syndromes and suggests that others may await discovery.

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
